Navigation Links
Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications
Date:12/21/2009

-- Phase III trials of OGX-011 in first- and second-line advanced prostate cancer and non-small cell lung cancer, expected to begin in 2010 and early 2011 --

-- Significantly strengthens Teva's oncology offerings with novel therapeutic designed to target resistance to cancer treatments --

JERUSALEM, Israel, BOTHELL, WA and VANCOUVER, Canada, Dec. 21 /PRNewswire-FirstCall/ - Teva Pharmaceutical Industries Ltd. ( TEVA) and OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that they have entered into a global license and collaboration agreement to develop and commercialize OGX-011, as well as an agreement to purchase shares in OncoGenex. OGX-011 is a Phase III cancer therapy designed to inhibit cancer treatment resistance. OGX-011 is expected to be used as adjunct therapy to enhance the effectiveness of chemotherapy and has shown promising results when added to currently available chemotherapies in several tumor types addressing a significant unmet medical need.

The agreement will further enhance Teva's oncology offerings and strengthen its global branded product pipeline with a promising product candidate entering three Phase III trials involving large patient populations. Teva and OncoGenex will collaborate on a global Phase III clinical program, with two Phase III clinical trials expected to be initiated in 2010: a Phase III Study for Second-line Chemotherapy in Men with Metastatic Castrate Resistant Prostate Cancer (CRPC) and a Phase III Study in First-Line Chemotherapy for Metastatic CRPC. An additional Phase III Study in First-Line Treatment of Advanced, Unresectable Non-Small Cell Lung Cancer (NSCLC) is intended to be initiated by early 2011.

Under the terms of the collaboration and share purchase agreements, Teva will provide OncoGenex with a $60 million initial cash payment, whi
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ATS Medical Expands Open Pivot Heart Valve Offerings
2. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
3. BioLife Solutions Expands Scientific Advisory Board
4. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
5. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
6. Pharsight Expands Strategic Consulting Services Team
7. Validus Pharmaceuticals Expands Product Portfolio with Acquisition of Bipolar Drug: Equetro(R)
8. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
9. AQUISS Expands Into Significant New Territory
10. NanoBio Expands Drug Development Team for Its Anti-Infective Products
11. BitWine (TM) Nutrition Advisors Network Expands Roster of Licensed Dietitians and Nutritionists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... WI (PRWEB) , ... September 01, 2015 , ... In ... Venice expertly transports the reader to a not-so-distant future faced with an Ebola pandemic ... beautiful professional who overcomes personal tragedy to enter the world of counterterrorism, and who ...
(Date:9/1/2015)... ... September 01, 2015 , ... VetStem Biopharma announces new Clinical ... joint problems can be caused by injuries and abnormalities of the cervical spine. ... or of the spinal cord itself. This can manifest itself as any or ...
(Date:9/1/2015)... ... September 01, 2015 , ... Leading CEOs, ... and pain management space join prominent academics and key investors for Neuro Advance ... Medical School in Boston. , Neuro Advance Boston focuses on the latest ...
(Date:9/1/2015)... N.C. , Sept. 1, 2015   ... to facilitating the relationship between doctors and patients, ... Durham, N.C. -based venture capital ... strength and business association with Bull City Venture ... Malik , Medfusion Founder and Executive Chairman. "Both ...
Breaking Biology Technology:Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 2Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 3VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 2VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 3Neuro Advance Boston Brings Together Leading Neuroscience Experts on October 14 at Harvard Medical School 2Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 2Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 3
... FOR TUESDAY, OCTOBER 28, SAN DIEGO, Oct. 22 ... that the Company will report its third,quarter 2008 financial ... 2008. Neurocrine will host a live conference call and ... update Tuesday,afternoon, October 28, 2008 at 5:00 p.m. Eastern ...
... $247 Million -, Third Quarter 2008 Highlights:, -- Total ... -- Total revenues without Osteocel of $62.5 million; up 62.3% from the ... Gross profit of $54.7 million; up 73.2% from the third quarter of 2007, ... third quarter of 2007, -- GAAP loss per share for ...
... Third Quarter 2008 Revenue Increased 7 Percent to $3.9 Billion, Third Quarter ... Third Quarter 2007 GAAP Earnings Per Share ... Billion to ... Billion, Full Year Adjusted EPS Guidance Raised from $4.25 - $4.45 to $4.45 ...
Cached Biology Technology:Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results 2Nuvasive Reports Third Quarter 2008 Financial Results 2Nuvasive Reports Third Quarter 2008 Financial Results 3Nuvasive Reports Third Quarter 2008 Financial Results 4Nuvasive Reports Third Quarter 2008 Financial Results 5Nuvasive Reports Third Quarter 2008 Financial Results 6Nuvasive Reports Third Quarter 2008 Financial Results 7Nuvasive Reports Third Quarter 2008 Financial Results 8Nuvasive Reports Third Quarter 2008 Financial Results 9Nuvasive Reports Third Quarter 2008 Financial Results 10Nuvasive Reports Third Quarter 2008 Financial Results 11Nuvasive Reports Third Quarter 2008 Financial Results 12Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 2Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 3Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 4Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 5Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 6Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 7Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 8Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 9Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 10Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 11Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 12Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 13Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 14Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 15Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 16Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 17Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 18Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 19Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 20Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 21Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 22Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 23Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 24
(Date:8/20/2015)... 2015 The wearable technology market has ... and healthy. However, wearable technology has the potential ... help improve diagnostic capabilities and therapeutic outcomes. Today, ... Wearable Technologies Conference 2015 , where Barrett ... in healthcare.    "Over the past ...
(Date:8/18/2015)... DUBLIN , Aug. 17, 2015 ... the addition of the "Global Biometric Authentication ... Application - Estimation & Forecast, 2015-2020" report ... biometric authentication and identification systems market is expected ... from 2015 to 2020 and generate over $25 ...
(Date:8/12/2015)... 12, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that four of its fingerprint ID ... officially been named FIDO Certified™ by the Fast ... certification, Synaptics, Natural ID™ fingerprint solutions are fully ... (UAF) standard and are interoperable among other products ...
Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3
... the skeletons of organisms contain small amounts of impurity ... elements provide important clues to past environments, a considerable ... contents to the ancient environments in which an organism ... Science magazine, Allison Stephenson, a Ph.D. candidate ...
... of the mystery underlying a childhood eye disease. New research ... missing or extra pieces of DNA. The missing or extra ... of A research team had previously shown how they play a ... disease that can lead to blindness. In their current study, published ...
... not food allergies at all. This is what Cornelia ... in a study with 419 patients, as presented in ... (Dtsch Arztebl Int 2008; 105[42]: 715-23). http://www.aerzteblatt.de/v4/archiv/pdf.asp?id=61998 ... only confirmed in 214 patients. Thus, food allergies are ...
Cached Biology News:Bare bones of crystal growth: Biomolecules enhance metal contents in calcite 2
ABCA1 Immunogen: Mouse ABCA1-expressing HeLa stable transfectants. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Purified Mouse anti-Hu Actopaxin (pS8) Storage Temperature: Refrigerate(2 to 8C)...
Blank Calibration Particles, 3.0-3.4 mu m 5 ml...
Goat polyclonal to SIAH Interacting Protein ( Abpromise for all tested applications)....
Biology Products: